Blood-borne indicators of breast cancer and their use in experimental, medical oncologic, and prevention studies

[1]  R. Dickson,et al.  The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  R. Dickson,et al.  Growth factors in breast cancer. , 1995, Endocrine reviews.

[3]  T. Imazawa,et al.  Serum concentrations of hepatocyte growth factor in breast cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  J. Kovarik,et al.  Absence of p53 autoantibodies in a significant proportion of breast cancer patients. , 1995, British Journal of Cancer.

[5]  L. Amundadottir,et al.  Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  V. Chinchilli,et al.  Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Jarosz,et al.  Elevated levels of pro-cathepsin-d in the plasma of breast-cancer patients. , 1995, International journal of oncology.

[8]  M. Swift.  Ionizing radiation, breast cancer, and ataxia-telangiectasia. , 1994, Journal of the National Cancer Institute.

[9]  L. Seymour,et al.  Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. , 1994, British journal of cancer.

[10]  K. Sugano,et al.  [Clinical evaluation of serum ErbB-2 protein using enzyme immuno assay (ErbB-2 EIA [Nichirei])]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[11]  K. Sugano,et al.  [Clinical study of serum ErbB-2 protein using sandwich radioimmunometric assay (ErbB-2 IRMA 'Eiken')]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[12]  S. Leinster,et al.  The relationship between serum p53 autoantibodies and characteristics of human breast cancer. , 1994, British Journal of Cancer.

[13]  S. Barni,et al.  Serum Levels of Insulin-Like Growth Factor-I in Operable Breast Cancer in Relation to the Main Prognostic Variables and their Perioperative Changes in Relation to those of Prolactin , 1994, Tumori.

[14]  Shuang Huang,et al.  Elevated serum levels of transforming growth factor-α in breast cancer patients , 1994 .

[15]  C. Peschle,et al.  Interleukin‐6 serum levels in patients with gynecological tumors , 1994, International journal of cancer.

[16]  J. Richie,et al.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. , 1994, Journal of the National Cancer Institute.

[17]  D. Page.  The epidemiology of tumor markers in breast cancer management: prognostic markers. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  O. Kallioniemi,et al.  Elevated erbB‐2 oncoprotein levels in preoperative and follow‐up serum samples define an aggressive disease course in patients with breast cancer , 1994, Cancer.

[19]  A. Harris,et al.  Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo , 1993 .

[20]  M. Costantini,et al.  Suramin and serum insulin-like growth factor levels in metastatic cancer patients. , 1993, Anticancer research.

[21]  F. Balkwill,et al.  A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. , 1993, Cancer research.

[22]  A. Wellstein,et al.  Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. , 1993, Cancer research.

[23]  B. Hulka,et al.  HRAS protooncogene polymorphism and breast cancer. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  G. Francini,et al.  Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  R. Dickson,et al.  The role of cathepsin D in the invasiveness of human breast cancer cells. , 1993, Cancer research.

[26]  N. Davidson,et al.  Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. , 1992, Cancer research.

[27]  K. Sugano,et al.  [Development of sandwich radioimmunometric assay for serum c-erbB-2 oncogene product and its significance in diagnosing breast carcinoma]. , 1991, Rinsho byori. The Japanese journal of clinical pathology.

[28]  E. Nexo,et al.  A Mr 43,000 epidermal growth factor-related protein purified from the urine of breast cancer patients. , 1990, Cancer research.

[29]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[30]  A. Cuschieri,et al.  Serum proteinase-like peptidase activities and proteinase inhibitors in women with breast disease. , 1984, European journal of cancer & clinical oncology.

[31]  C. Kosloff,et al.  Lobular carcinoma in situ of the breast Detailed analysis of 99 patients with average follow‐up of 24 years , 1978, The American journal of surgical pathology.

[32]  D. Ingram,et al.  Timing of surgery during the menstrual cycle for breast cancer: possible role of growth factors. , 1995, European journal of cancer.

[33]  J. Weissfeld,et al.  Evaluation of oncogene-related proteins in serum. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  Se Rt,et al.  Menstrual timing of treatment for breast cancer. , 1994 .

[35]  M. Miyamoto,et al.  Serum c-erbB-2 in breast cancer patients. , 1994, Acta oncologica.

[36]  M. Pincus,et al.  erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  P. Engstrom.  Predictors of future breast cancer risk. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  A. Friedl,et al.  Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. , 1993, European journal of cancer.

[39]  U. Moll,et al.  Mr 92,000 Type IV Collagenase Is Increased in Plasma of Patients with Colon Cancer and Breast Cancer , 1993 .

[40]  N. Normanno,et al.  Additive effects of c‐erbB‐2, c‐Ha‐ras, and transforming growth factor‐α genes on in vitro transformation of human mammary epithelial cells , 1992, Molecular carcinogenesis.

[41]  B. Trock.  Biologic markers as predictors of risk in aerodigestive tract cancers. , 1992, Advances in experimental medicine and biology.

[42]  J. Kovarik,et al.  Clinical experience with the testing of serum proteinase activity by cathepsin B-like sensitive amino acid derivatives of 7-amino-4-methylcoumarine. , 1987, Neoplasma.

[43]  Mel'nikov La,et al.  Antiprotease activity of the blood serum of patients with the disseminated form of breast cancer before and after combined treatment , 1983 .